Get started
Live feed
PRReleasevia Quantisnow
Fate Therapeutics Inc. logo

Fate Therapeutics Selected for U.S. FDA Chemistry, Manufacturing, and Controls Development and Readiness Pilot Program to Support Manufacturing Readiness of FT819

ByQuantisnow··Wall Street's wire, on your screen.
Stocks in this Quantisnow insight

Historical context for FATE

Across the 16 sessions after earlier FATE headlines, the stock closed higher 7 times and lower 8 times, with a median move of 4.7% in either direction. This shows timing only: many things move a stock in a session, and these figures do not show that any headline caused a move.

FATE close-to-close change in the session after earlier headlines
SessionEarlier headlineFATESPY
May 4, 2026Fate Therapeutics Announces Three Presentations at the 2026 ASGCT Annual Meeting Highlighting Off-the-Shelf CAR T-cell Therapy Pipeline for Cancer and Autoimmune Diseasesand 1 other headline that session+17.6%-0.4%
Apr 30, 2026Fate Therapeutics Announces Data Presentation of FT819 Off-the-Shelf CAR T-Cell Product Candidate for Systemic Lupus Erythematosus (SLE) at the CCR – East 2026 Meeting+0.8%+1.0%
Apr 16, 2026Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting+6.2%+0.2%
Apr 9, 2026Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences+7.6%+0.6%
Apr 6, 2026Fate Therapeutics Reports New Employee Inducement Award Under Nasdaq Listing Rule 5635(c)(4)-2.5%+0.5%
Mar 5, 2026Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)-4.8%-0.6%

Keep researching FATE

Quantisnow market dataNASDAQ
Fate Therapeutics Inc. logo
FATE
Fate Therapeutics Inc.
Market cap
30-day
Sector
Health Care
Industry
Biotechnology: Biological Products (No Diagnostic Substances)
Listed since
2013
Get push alerts for FATE

Follow FATE and get a push notification the moment its next story breaks.

Full FATE profile on Quantisnow

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track FATE (Fate Therapeutics Inc.) and more on Quantisnow.